retatrutide trial results weight loss VisualAbstract: reduces body by 17.5% in patients with obesity Retatrutide hits 28.3% weight loss

Description

Metabolic Health Goals Adults seeking a more comprehensive provider-guided plan for weight, insulin resistance risk, energy, and long-term health

BBS or POMC, PCSK1, or LEPR Deficiency The safety and effectiveness of IMCIVREE have been established to reduce excess body weight and maintain weight reduction long term in pediatric patients aged 2 years and older with obesity due to: BBS [see Clinical Studies (14.2, 14.4)] POMC, PCSK1, or LEPR deficiency with variants in POMC, PCSK1, or LEPRgenes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS) [see Clinical Studies (14.3, 14.4)] Use of IMCIVREE for these indications is supported by evidence from one 66-week trial, which included a 14-week, randomized, double-blind, placebo-controlled period followed by a 52-week open-label period, and included 22 pediatric patients with BBS aged 6 to 17 years (Trial 2)

"We just need to monitor [these patients] closely, because there were some obstetric outcomes that we need to keep an eye on," she told Live Science

Imaging dynamic insulin release using a fluorescent zinc indicator for monitoring induced exocytotic release (ZIMIR)

19 Amounts committed to an employees HRA that are not used by the employee generally roll over and can be used in future years, but any balance may revert back to the employer if the employee leaves his or her job